Targets and validation of Salvia miltiorrhiza in myopia through network pharmacology

Authors: Lu Xiaonan,  Li Jie,  An Guangqi,  Liu Zhenhui,  Liang Chunyu,  Dai Shuzhen
DOI: 10.3760/cma.j.cn115989-20231209-00205
Published 2024-04-10
Cite as Chin J Exp Ophthalmol, 2024, 42(4): 322-328.

Abstract                            Download PDF】 【Read Full Text

Objective

To explore and validate the targets of Salvia miltiorrhiza in myopia using network pharmacology and molecular docking technology.

Methods

The TCMSP database was used to extract the targets of Salvia miltiorrhiza.GeneCards, DisGeNET, Malacard and OMIM databases were used to extract the myopia-related targets.The target intersection was taken, and the intersecting targets were selected to extract the corresponding active ingredients of traditional Chinese medicine (TCM) and construct the pharmacological regulatory network of TCM using Cytoscape.The protein interaction network map for the key target genes was constructed using the String database, and the relevant proteins were selected to download the three-dimensional structures of the active ingredients from the PubChem database, and molecular docking was performed using AutoDockvina software.Twelve 3-week-old guinea pigs were induced with lens-induced myopia (LIM) in the right eye and randomly divided into normal saline group and sodium danshensu group, with 6 animals in each group.During the maintenance of LIM, periocular injection of 1 ml normal saline or sodium danshensu was performed daily.The contralateral eye was used as a negative control.On days 0, 14, and 28 of the experiment, the axial length of both eyes was measured by A-scan ultrasonography, and the refractive status was assessed with a streak retinoscope.To avoid individual differences, relative spherical equivalent (treated eye-contralateral eye) and relative axial length (treated eye-contralateral eye) were compared.On day 28, the relative expression levels of hypoxia-inducible factor-1α (HIF-1α) and transforming growth factor-β1 (TGF-β1) proteins were determined by Western blot.The feeding and use of laboratory animals followed the 3R principle, and the research program was approved by the Ethics Committee of Experimental Animal Center of Zhengzhou University (No.ZZU-LAC 202320405[02]).

Results

Sixteen intersecting key targets were screened for myopia and TCM components derived from Salvia divinorum.A TCM network pharmacology map and protein interaction map were constructed with Salvia divinorum as a drug candidate, and the corresponding proteins of target genes, such as MMP2TGFB1, and MMP9 were screened to perform molecular docking with the active ingredients, such as lignocellulosic acid, danshensu, tanshinone ⅡA, and so on.After 14 days of induction, the relative spherical equivalent and relative axial length were (-4.67±1.03)D and (0.67±0.26)mm in sodium danshensu group, and (-6.30±1.22)D and (1.08±0.34)mm normal saline group, indicating slower myopia progression and axial elongation in sodium danshensu group, and the differences were statistically significant (t=2.412, P=0.039; t=2.750, P=0.049). The relative expression levels of HIF-1α protein were 0.20±0.01, 1.29±0.05 and 0.63±0.02, and the relative expression levels of TGF-β1 protein were 0.93±0.05, 0.25±0.01 and 0.74±0.05 in the negative control, normal saline and sodium danshensu groups, respectively.The expression of HIF-1α protein was higher in sodium danshensu group than in negative control group but lower than in the normal saline group, and the expression of TGF-β1 protein was lower in sodium danshensu group than in negative control group but higher than in the normal saline group, showing statistically significant differences (all at P<0.05).

Conclusions

Natural compounds extracted from Salvia divinorum extracts may serve as potential drug candidates to combat scleral hypoxia and improve scleral extracellular matrix remodeling.

Key words:

Myopia; Sclera remolding; Network pharmacology; Salvia miltiorrhiza; Hypoxia

Contributor Information

Lu Xiaonan

Department of Ophthalmology, Henan Provincial People’s Hospital, Henan Eye Hospital, Zhengzhou University People’s Hospital, Zhengzhou 450003, China

Li Jie

Department of Ophthalmology, Henan Provincial People’s Hospital, Henan Eye Hospital, Zhengzhou University People’s Hospital, Zhengzhou 450003, China

An Guangqi

Department of Ophthalmology, The First Afflicted Hospital of Zhengzhou University, Zhengzhou University Fundus Disease Institute, Zhengzhou 450000, China

Liu Zhenhui

Department of Ophthalmology, Henan Provincial People’s Hospital, Henan Eye Hospital, Zhengzhou University People’s Hospital, Zhengzhou 450003, China

Liang Chunyu

Department of Ophthalmology, The First Afflicted Hospital of Zhengzhou University, Zhengzhou University Fundus Disease Institute, Zhengzhou 450000, China

Dai Shuzhen

Department of Ophthalmology, Henan Provincial People’s Hospital, Henan Eye Hospital, Zhengzhou University People’s Hospital, Zhengzhou 450003, China

(Read 6 times, 1 visits today)